QPX2014
/ Shionogi
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
July 09, 2025
Antibiotics and non-traditional antimicrobial agents for pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials.
(PubMed, Expert Opin Investig Drugs)
- "Traditional agents in clinical development include β-lactam/β-lactamase inhibitors (funobactam, taniborbactam, QPX2014-xeruborbactam), aminoglycosides (apramycin), polymyxin derivatives (upleganan, MRX-8, and SPR741), fluoroquinolones (MP-376), and lipopolysaccharide transport inhibitors (murepavadin). Non-traditional antibiotics in clinical development include anti-virulence agents (fluorothiazinone), monoclonal antibodies (INFEX-702, TRL-1068, and CMTX-101), bacteriophages (AP-PA02, YPT-01, BX004-A, and WRAIR-PAM-CF1), and miscellaneous agents (AR-501, PLG-0206, SNSP-113, OligoG CF-5/20, and ALX-009). A considerable number of antimicrobial agents, some with novel mechanisms of action, are in clinical phases of development for treating Pseudomonas aeruginosa infections. The urgent need for more therapeutic options necessitates the rapid optimization of progress to introduce new agents into clinical practice."
Journal • Review • Infectious Disease
September 23, 2022
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
(clinicaltrials.gov)
- P1 | N=82 | Completed | Sponsor: Qpex Biopharma, Inc. | Recruiting ➔ Completed
Combination therapy • Trial completion • Infectious Disease
July 20, 2022
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
(clinicaltrials.gov)
- P1 | N=86 | Recruiting | Sponsor: Qpex Biopharma, Inc. | Completed ➔ Recruiting | Trial completion date: Mar 2022 ➔ Sep 2022 | Trial primary completion date: Feb 2022 ➔ Aug 2022
Combination therapy • Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease
April 20, 2022
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
(clinicaltrials.gov)
- P1 | N=71 | Completed | Sponsor: Qpex Biopharma, Inc. | Recruiting ➔ Completed
Combination therapy • Trial completion • Infectious Disease
February 14, 2022
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
(clinicaltrials.gov)
- P1 | N=71 | Recruiting | Sponsor: Qpex Biopharma, Inc. | Trial completion date: Aug 2021 ➔ Jun 2022 | Trial primary completion date: Aug 2021 ➔ Mar 2022
Combination therapy • Trial completion date • Trial primary completion date • Infectious Disease
December 21, 2021
Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=12; Completed; Sponsor: Qpex Biopharma, Inc.; Recruiting ➔ Completed; Trial completion date: Feb 2022 ➔ Nov 2021
Clinical • Trial completion • Trial completion date • Infectious Disease
December 01, 2021
Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=12; Recruiting; Sponsor: Qpex Biopharma, Inc.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease
October 11, 2021
P1, Single Dose Drug-Drug Interaction Study of IV QPX2014 Alone and Combined With QPX7728 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=12; Not yet recruiting; Sponsor: Qpex Biopharma, Inc.
Clinical • New P1 trial • Infectious Disease
December 08, 2020
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
(clinicaltrials.gov)
- P1; N=88; Recruiting; Sponsor: Qpex Biopharma, Inc.; Not yet recruiting ➔ Recruiting
Clinical • Combination therapy • Enrollment open • Infectious Disease
September 30, 2020
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
(clinicaltrials.gov)
- P1; N=88; Not yet recruiting; Sponsor: Qpex Biopharma, Inc.; Trial completion date: May 2021 ➔ Aug 2021; Trial primary completion date: May 2021 ➔ Aug 2021
Clinical • Combination therapy • Trial completion date • Trial primary completion date • Infectious Disease
1 to 10
Of
10
Go to page
1